Cancer Research

The most formidable barrier to treating aggressive brain cancer may not be the physical skull or the blood-brain barrier, but the cellular invisibility cloak that allows these tumors to ignore the body’s natural defenses. For decades, the primary strategy in oncology has been to train the immune

The transition from curative efforts to palliative management represents one of the most emotionally charged and ethically complex phases in modern oncology. Patients facing an incurable diagnosis no longer view medical interventions solely through the lens of survival statistics but rather through

Ivan Kairatov is a leading biopharma expert whose career has been defined by bridging the gap between fundamental molecular research and clinical innovation. With extensive experience in research and development, he has spent years investigating how cellular mechanics can be harnessed to treat

The human brain possesses an intricate waste-clearance system that, when functioning correctly, prevents the toxic buildup of proteins associated with cognitive decline. However, for millions of individuals, this biological janitorial service fails, leading to the relentless progression of

The sudden transformation of multiple myeloma from a terminal diagnosis to a manageable chronic condition reached a pivotal junction with the Food and Drug Administration's recent decision to grant full approval to a high-impact combination therapy. By pairing the bispecific antibody Tecvayli with

Ivan Kairatov is a seasoned Biopharma expert with a rich background in research and development, specializing in the cutting edge of oncological innovation. In this discussion, we explore the breakthrough development of armored CAR-T cells designed to dismantle the physical and chemical barriers of